Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
More than 50% of all new prescriptions written in the United States today for the ongoing treatment of schizophrenia are for atypical antipsychotics. This is an impressive accomplishment, especially when only 10%—perhaps far less in some countries—of worldwide prescriptions are written for atypical antipsychotics. There is emerging interest in whether the newer atypical antipsychotics should generally be substituted for typical antipsychotics and in how to distinguish among the atypical agents when selecting treatment for an individual patient.’ ‹
Save
Cite
Advertisement
GAM ID: sidebar-top